TPO and Thrombocytopenia: Unlike prior broad oncology reviews, this study synthesizes recent randomized and real-world data on thrombopoietin receptor agonists (TPO-RA), most notably the phase III avatrombopag study and global RECITE trial of romiplostim presented at the ASCO 2025, to aid in presenting an algorithm tailored specifically to gastrointestinal malignancies, which happens to be one of the largest solid tumor subgroups affected by chemotherapy-induced thrombocytopenia (CIT) [3,4].